Efficacy and safety of itraconazole use in infants

Chen, Shuang; Sun, Kai-Yi; Feng, Xiaowei; Ran, Xin; Lama, Jebina; Ran, Yuping

doi:10.1007/s12519-016-0034-x

Cited by 26 publications

(18 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 31 ] Itraconazole dosage of 5 mg/kg body weight has been used in children and infants with superficial dermatophytosis and found to be effective and safe. [ 39 40 ] In adults a fixed-dose regimen of 250 mg/day terbinafine and 200 mg/day itraconazole is recommended. [ 3 4 ]…”

Section: Discussionmentioning

confidence: 99%

Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: A randomized controlled parallel group open labeled trial with clinico-mycological correlation

2020

View full text Add to dashboard Cite

Background: There is a rising prevalence of dermatophyte infection especially in the tropics. It has been observed that the antifungals are not as effective as they used to be. Aims: To determine the effectiveness of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection. Materials and Methods: Study design was a randomized parallel group trial. Patients were randomly divided into five parallel arms in which two of the standard drugs in recommended doses were compared with their double doses and with combination of both the drugs. Patients were followed up every 2 weeks. Outcomes were assessed at 4 and 8 weeks. Cure was considered as complete clinical resolution of the lesions. Fungal culture and sensitivity were done by disk diffusion method for all patients. Parametric one-way analysis of variance ( F test) and Chi-square test were used for the analysis. Results: Two-hundred seventy-five patients were included in the study. Itraconazole containing groups showed significantly higher cure rates than terbinafine only groups both at 4 and 8 weeks ( P < 0.001). Itraconazole containing groups, when compared against each other, were not found to be significantly different. The outcomes between terbinafine only groups were also not significantly different. Cure rates at 8 weeks were found to be greater than that at 4 weeks for all groups which were found to be highly significant ( P < 0.001). Conclusions: Itraconazole seems to be more effective than terbinafine. There is no benefit in increasing the dose or using a combination regimen in the treatment of tinea. Prolonged duration of treatment is required for complete cure.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: A randomized controlled parallel group open labeled trial with clinico-mycological correlation

2020

View full text Add to dashboard Cite

show abstract

“…It interferes with 14-α- demethylase, a cytochrome P450-dependent enzyme, which inhibits the conversion of lanosterol to 14-demethyl lanosterol. Itraconazole oral suspension has a bioavailability of 60% that can be improved if given after a fatty meal [43]. A peak plasma concentration is reached within 4 h, but absorption appears to be dose dependent.…”

Section: Itraconazolementioning

confidence: 99%

Treatment of Tinea Capitis

Alkeswani

Cantrell²,

Elewski

2019

Skin Appendage Disord

View full text Add to dashboard Cite

Tinea capitis is a common fungal infection of the hair of the scalp affecting predominately prepubertal children. In the US, griseofulvin has been considered a first-line therapy agent for tinea capitis since the 1960s. However, it has been falling out of favor due to significant treatment failure, high cost, and long duration of treatment. Other antifungal agents have been researched as an alternative to griseofulvin. This paper will review the relevant pharmacologic properties, dosing, cost, efficacy, and adverse events profile for griseofulvin, terbinafine, itraconazole, fluconazole, and some adjuvant therapy options such as selenium sulfide shampoos and topical ketoconazole.

show abstract

“…Only liver function and blood routine examination are needed before and after the treatments in the outpatient clinic. Nevertheless, because itraconazole is associated with a range of potential drug interactions (Chen et al, 2016), attention must be taken to note any other concurrent medications that infants may use. Our findings from this study provide a strong rational basis for future clinical evaluation of itraconazole for the treatment of IH.…”

Section: Effects Of Itraconazole On Infant Hemangioma In Vitromentioning

confidence: 99%

“…For more than 30 years, itraconazole has been widely used in the treatment of fungal diseases in infants and young children (Chen et al, 2016;Lestner et al, 2013;). Intriguingly, itraconazole has been demonstrated to possess therapeutic effects against a variety of human cancers (Pantziarka et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor–D/PI3K/Akt/mTOR Pathway

Chen

Zhuang

Sun

et al. 2019

Journal of Investigative Dermatology

Self Cite

View full text Add to dashboard Cite

Infantile hemangioma is the most common benign vascular tumor of infancy. We have previously reported that itraconazole, a common antifungal agent, can clinically improve or cure infantile hemangioma; however, the underlying molecular mechanisms are still unclear. Here, we show that itraconazole treatment significantly inhibits proliferation and promotes apoptosis of the endothelial cells of mouse hemangioma cell line and infantile primary hemangioma endothelial cell. Itraconazole also remarkably reduced angiogenesis of hemangioma endothelial cell in vitro. We further performed transcriptome profiling via mRNA microarrays in hemangioma endothelial cell upon itraconazole treatment, and identified cytokineecytokine receptor interaction as the top significantly enriched pathway. Importantly, itraconazole significantly reduced plateletderived growth factoreD level, resulting in suppression of platelet-derived growth factoreb activation and inhibition of its downstream effectors, such as PI3K, Akt, 4E-BP1, and p70S6K, which are important for cellular growth and survival of infantile hemangioma. In conclusion, our results suggest that platelet-derived growth factoreD is a target of itraconazole in infantile hemangioma.

show abstract

Efficacy and safety of itraconazole use in infants

Cited by 26 publications

References 72 publications

Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: A randomized controlled parallel group open labeled trial with clinico-mycological correlation

Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: A randomized controlled parallel group open labeled trial with clinico-mycological correlation

Treatment of Tinea Capitis

Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor–D/PI3K/Akt/mTOR Pathway

Contact Info

Product

Resources

About